Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Multicentre Randomized Controlled Trial of a "Freeze All and Transfer Later" Versus a Conventional "Fresh Embryo Transfer" Strategy for Assisted Reproductive Technology (ART) in Women With a Regular Menstrual Cycle
Brief Summary: The purpose of this study is to compare conventional fresh embryo transfer with a "freeze all and transfer later strategy" in assisted reproductive technology in terms of ongoing pregnancy rates, live birth rates as well as perinatal outcomes.


Options:
A: Inclusion Criteria:

* Women diagnosed as PCOS according to Chinese PCOS diagnosis criteria;
* Women who have ≥1 years history of infertility;
* Women aged ≥20 and \<35 years old;
* Women with body weight ≥40kg;
* Women who have at least one of the following indications for IVF or ICSI:

  1. Ovulation dysfunction and failed to become pregnant from ovulation induction treatment;
  2. Tubal factors: unilateral or bilateral tubal obstruction, adhesion, unilateral or bilateral Salpingectomy or tubal ligation;
  3. Male factors: oligoasthenozoospermia, obstructive azoospermia;
* Women who are undergoing their first cycle of IVF or ICSI;
* Women who retrieved oocytes number \> 3;
* Women who are capable of giving informed consent.

Exclusion Criteria:

* Women who underwent unilateral ovariectomy;
* Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion;
* Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
* Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times;
* Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy;
* Women who has developed severe OHSS before oocyte pick-up day;
* Women with retrieved oocytes number ≤3;
* Women who are unable to comply with the study procedures.
B: Inclusion Criteria:

* AMH (Anti-Müllerian hormone) \> 6.28 pmol/L (Roche Elecsys assay)
* Female age 18 years to less than 40 years
* 1, 2 or 3 IVF/ICSI cycle with oocyte aspiration
* Regular menstrual cycle between 24 and 35 days
* BMI between 18 and 35
* Two ovaries
* Can and will sign informed consent

Exclusion Criteria:

* Women who do not fulfil the inclusion criteria
* Endometriosis stage III to IV
* Ovarian cysts with diameter \> 30 mm at day of start of stimulation
* Submucosal fibroids
* Women with severe co-morbidity (IDDM, NIDDM, gastrointestinal, cardiovascular, pulmonary, liver or kidney disease)
* Dysregulation of thyroid disease
* Not danish or English speaking women
* Contraindications or allergies to use of Gonadotrophins or GnRH antagonists
* TESA (testicular sperm aspiration)
* OD (oocyte donation)
* Previous inclusion in the study
C: Inclusion Criteria (pre-stimulation):

* Age up to 42 years

Exclusion Criteria (pre-stimulation):

* MESA and TESE patients
* At least one partner carrier of a chromosomal abnormality
* Egg donor cycle (sperm donor is acceptable)
* Gender selection cycles
* Thaw cycles
* Any patient who cannot have a fresh embryo transfer
* FSH above 12 or AMH less than 1
D: Inclusion Criteria:

* Undergoing In-vitro fertilization (IVF) treatment
* Number of previous failed embryo transfers ≤ 2
* Permanent living in Viet Nam
* Ovarian hyperstimulation with Gonadotropin releasing hormone (GnRH) antagonist protocol
* Eligible for embryo transfer (ET) on day 3
* Having at least one top-quality embryo on day 3.
* Number of embryos transferred ≤ 2
* Willing to participate in the study
* Not to participate in another IVF study at the same time

Exclusion Criteria:

* women with polycystic ovary syndrome
* In vitro maturation (IVM) cycles
* Oocyte donation cycles
* Using GnRH agonist for triggering

Answer: B